To investigate the effect of IL-6

we added IL-6 neutralizing antibodies (MQ2-13A5, BD Biosciences) and the appropriate rat IgG1 isotype control (50 ng/mL). Basic descriptive statistics were used to describe the patient population. Data involving two time points within one population were compared using the Wilcoxon matched pair test. For differences in median between two independent groups, the Mann–Whitney U test was used to test for significance. Significance was accepted at p<0.05 indicated in the graphs by * or p<0.001 indicated by **. The authors thank W. de Jager from the Center for Molecular and Cellular Intervention for his assistance with Tigecycline clinical trial the Luminex analysis, M. Klein for technical assistance

with FACS sorting and J. Meerding for performing the CFSE assays. This study was supported by the Wilhelmina Children’s Hospital Research Fund. B. J. Prakken was supported by grants from the Dutch Organization for Scientific Research (NWO VIDI innovation grant) and the Dutch Arthritis Foundation. Conflict JAK inhibitor review of interest: The authors declare no financial or commercial conflict of interest. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. “
“Thymus colonisation and thymocyte positioning are regulated by interactions between CCR7 and CCR9, and their respective ligands, CCL19/CCL21 and CCL25. The Interleukin-2 receptor ligands of CCR7 and CCR9 also interact with the atypical receptor CCRL1 (also known as ACKR4), which is expressed in the thymus and has recently been reported to play an important role in normal αβT-cell development. Here, we show that CCRL1 is expressed within the thymic cortex, predominantly

by MHC-IIlowCD40− cortical thymic epithelial cells (TECs) and at the subcapsular zone by a population of podoplanin+ TECs in mice. Interestingly, CCRL1 is also expressed by stromal cells which surround the pericytes of vessels at the corticomedullary junction, the site for progenitor cell entry and mature thymocyte egress from the thymus. We show that CCRL1 suppresses thymocyte progenitor entry into the thymus, however, the thymus size and cellularity are the same in adult wild-type and CCRL1−/− mice. Moreover, CCRL1−/− mice have no major perturbations in T-cell populations at different stages of thymic differentiation and development, and have a similar rate of thymocyte migration into the blood. Collectively, our findings argue against a major role for CCRL1 in normal thymus development and function. This article is protected by copyright. All rights reserved “
“Epidemiological evidence on the relationship between vitamin D receptor (VDR) polymorphisms and periodontal disease is inconsistent.